![]() Usage of Nucleo CMP Forte in the combined treatment of patients has more expressed positive influence on problems with walking. Significance was set at P0.05) and 33.3% (χ 2=6.171, P0.05) and 50% (χ 2=2.859, P>0.05) of ones respectively, pain/discomfort bothered less than 25% (χ 2=4.267, P<0.05) patients of the group A and 33.3% (χ 2=6.171, P<0.05) of the group B, anxiety/depression decreased in 58.3% (χ 2=6.063, P<0.05) and 66.7% (χ 2=6.954, P<0.05), respectively.Ĭonclusion: Patients of both groups noted the positive effect of treatment. Esta web utiliza cookies propias para facilitar la navegación y cookies de terceros para obtener estadísticas de uso y satisfacción. Entdecken Sie NUCLEO CMP Forte 30 Vitamin Capsules Medicine Nervous System Disorder Treatment in der groen Auswahl bei eBay. We used non-parametric test χ 2 to evaluate efficacy of therapy. Patients filled questionnaire of life quality EQ-5D-3L (Ukraine 2004, EuroQol) on the first and tenth day of treatment. Inactive Ingredients: Citric acid, Sodium Citrate 2H2O, Magnesium stearate, Aerosil200, Mannitol. Uridine-5- disodium monophosphate (UMP disodium salt) 3 mg. They were compared into two groups: A 30 patients received standard treatment, B 29 diabetics additionally were taken Nucleo CMP Forte (1 capsule three times a day). Uridine-5-trisodium triphosphate (UTP trisodium salt) & Uridine-5-disodium diphosphate (UDP disodium salt) 3 mg. ![]() Methods: It was examined 59 (41≧9 years old) patients with type 2 DM and DPNP. The aim: To evaluate the efficacy of Nucleo CMP Forte (Cytidine 5- disodium monophosphate and Uridine 5- trisodium triphosphate) in the combined treatment of patients with DPNP. New medications in DPNP have to be studied. Introduction: The protocols of medical care of diabetic peripheral neuropathy (DPNP) are developed but positive effect cannot be achieved in all patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |